High Dose Daunorubicin Improves Survival in AML up to Age 60, Across All Cytogenetic Risk Groups Including Patients with Unfavorable Cytogenetic Risk, and FLT3-ITD Mutant AML: Updated Analyses from Eastern Cooperative Oncology Trial E1900
暂无分享,去创建一个
O. Abdel-Wahab | R. Levine | M. Tallman | H. Lazarus | E. Paietta | J. Rowe | Zhuoxin Sun | M. Litzow | H. Fernandez | Jay P. Patel | S. Luger | Ju-Whei Lee | M. Luskin